866-997-4948(US-Canada Toll Free)

EpiCast Report: Supportive Care in Oncology-Epidemiology Forecast to 2026

Published By :

GlobalData

Published Date : Dec 2017

Category :

Pharmaceutical

No. of Pages : 39 Pages

EpiCast Report: Supportive Care in Oncology - Epidemiology Forecast to 2026

Summary

Cancer is a broad term for a group of diseases characterized by uncontrolled cell proliferation. Worldwide, it is estimated that 14 million new cases of cancer are diagnosed each year, and 30-50% of those cases are preventable (WHO, 2017). Cancer is the second leading cause of death worldwide, with more than eight million deaths caused by cancer in 2015 (WHO, 2017).

GlobalData epidemiologists provide the number of diagnosed incident cases of all cancer treated with chemotherapy and the number of diagnosed incident cases of chemotherapy-treated cancers that develop associated conditions (neutropenia, anemia, oral mucositis, nausea and vomiting, and cachexia). GlobalData epidemiologists also provide the number of diagnosed incident cases of prostate, breast, and lung cancers, and those that progress to bone metastasis. To forecast the diagnosed incident and the five-year diagnosed prevalent cases of all cancer in the 7MM, GlobalData epidemiologists selected reputable international cancer databases and nationally representative, population-based studies that provided the diagnosed incidence or relative survival rates for all cancer in the 7MM.

In 2016, there were 933,412 diagnosed incident cases of all cancer receiving chemotherapy treatment in men and women, ages 18 years and older, in the 7MM. Combination therapy was more common, with 75.8% of cases receiving chemotherapy in conjunction with surgery, radiation, or both. The remaining cases, 24.2%, received chemotherapy alone. Of those receiving chemotherapy, anemia and nausea and vomiting were the most common conditions resulting from the treatment. In 2016, there were 809,204 cases of chemotherapy-induced anemia and 746,730 cases of chemotherapy-induced nausea and vomiting in the 7MM.

Scope

- The Supportive Care in Oncology EpiCast Report provides an overview of the risk factors and global trends of supportive care in oncology in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 7MM: diagnosed incident cases of all cancer; five-year diagnosed prevalent cases of all cancer; diagnosed incident cases of all cancer treated with chemotherapy; diagnosed incident cases all cancer treated with chemotherapy with chemotherapy induced condition (neutropenia, anemia, oral mucositis, nausea and vomiting, and cachexia); diagnosed incident cases of prostate cancer (men ages 35 years and older); diagnosed incident cases of breast cancer (women ages 20 years and older); diagnosed incident cases of lung cancer (men and women ages 20 years and older); diagnosed incident cases of prostate, breast, and lung cancer that metastasize to bone.
- The supportive care in oncology epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Supportive Care in Oncology EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global oncology and chemotherapy treatment market.
- Quantify patient populations in the global oncology and chemotherapy treatment market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chemotherapy induced conditions therapeutics in each of the markets covered.
- Understand magnitude of chemotherapy induced conditions.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Supportive Care Oncology: Executive Summary 4
2.1 Related Reports 6
2.2 Upcoming Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Global and Historical Trends 8
3.3 Forecast Methodology 10
3.3.1 Sources 10
3.3.2 Forecast Assumptions and Methods 17
3.4 Epidemiological Forecast for Supportive Care in Oncology (2016-2026) 23
3.4.1 Diagnosed Incident Cases of All Cancer 23
3.4.2 Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment 23
3.4.3 Diagnosed Incident Cases of Chemotherapy-Induced Conditions 24
3.4.4 Diagnosed Incident Cases of Prostate Cancer 25
3.4.5 Diagnosed Incident Cases of Prostate Cancer That Develop Bone Metastasis 26
3.4.6 Diagnosed Incident Cases of Breast Cancer 27
3.4.7 Diagnosed Incident Cases of Breast Cancer That Develop Bone Metastasis 28
3.4.8 Diagnosed Incident Cases of Lung Cancer 29
3.4.9 Diagnosed Incident Cases of Lung Cancer That Develop Bone Metastasis 30
3.4.10 Five-Year Diagnosed Prevalent Cases of All Cancer 31
3.5 Discussion 32
3.5.1 Epidemiological Forecast Insight 32
3.5.2 Limitations of Analysis 33
3.5.3 Strengths of Analysis 33
4 Appendix 34
4.1 Bibliography 34
4.2 About the Authors 37
4.2.1 Epidemiologists 37
4.2.2 Reviewers 37
4.2.3 Global Director of Therapy Analysis and Epidemiology 38
4.2.4 Global Head and EVP of Healthcare Operations and Strategy 38
4.3 About GlobalData 39
4.4 Contact Us 39
4.5 Disclaimer 39

1.1 List of Tables
Table 1: 7MM, Diagnosed Incident Cases of All Cancer, Men and Women, Ages 20 Years 23

1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment, Men and Women, Ages 18 Years 5
Figure 2: 7MM, Diagnosed Incident Cases of All Cancer With Chemotherapy-Induced Conditions, Men and Women, Ages 18 Years 6
Figure 3: 7MM, Age-Standardized Diagnosed Incidence of All Cancer, Men, Ages 18 Years, 2016-2026 9
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of All Cancer, Women, Ages 18 Years, 2016-2026 10
Figure 5: 7MM, Sources Used to Forecast Diagnosed Incident Cases of All Cancer 11
Figure 6: 7MM, Sources Used to Forecast Five-Year Diagnosed Prevalent Cases of All Cancer 12
Figure 7: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Prostate Cancer 13
Figure 8: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Breast Cancer 14
Figure 9: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Lung Cancer 15
Figure 10: 7MM, Sources Used to Forecast Chemotherapy-Induced Conditions 16
Figure 11: 7MM, Sources Used to Forecast Bone Metastasis in Prostate, Breast, and Lung Cancer 17
Figure 12: 7MM, Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment, Men and Women, Ages 18 Years 24
Figure 13: 7MM, Diagnosed Incident Cases of All Cancer With Chemotherapy-Induced Conditions, Men and Women, Ages 18 Years 25
Figure 14: 7MM, Diagnosed Incident Cases of Prostate Cancer, Men, Ages 35 Years 26
Figure 15: 7MM, Diagnosed Incident Cases of Prostate Cancer That Have Developed or Will Develop Bone Metastasis, Men, Ages 35 Years 27
Figure 16: 7MM, Diagnosed Incident Cases of Breast Cancer, Women, Ages 20 Years 28
Figure 17: 7MM, Diagnosed Incident Cases of Breast Cancer That Have Developed or Will Develop Bone Metastasis, Women, Ages 20 Years 29
Figure 18: 7MM, Diagnosed Incident Cases of Lung Cancer, Men and Women, Ages 20 Years 30
Figure 19: 7MM, Diagnosed Incident Cases of Lung Cancer That Have Developed or Will Develop Bone Metastasis, Men and Women, Ages 20 Years 31
Figure 20: 7MM, Five-Year Diagnosed Prevalent Cases of All Cancer, Men and Women, All Ages 32

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *